– MicroRNAs for risk assessment and treatment of venous thromboembolism
- Venous thromboembolism (VTE) is a highly prevalent disease, affecting around 1.1 million individuals in Europe each year, with 540,000 associated deaths.
- No modifiable risk-factors have been identified
- The current anti-coagulant treatment is associated with serious bleeding risks
- Find a drug that prevents VTE without serious side affects
- Specific microRNAs associated with a higher risk of VTE were found
- Targeted intervention of these microRNAs has the potential to effectively prevent VTE
- Treatment of VTE with microRNA therapeutic without bleeding risk
Opportunities for Collaboration
- Searching for a collaborative R&D deal with industrial partner
- Looking for a pharmaceutical partner with the expertise, commitment and financial strength to take it through the clinical phase and into the market.
- Population study
A pilot and a validation study show that specific miRNAs can be potential predictors of VTE and the risk of VTE is highly associated with miRNA level.
In-vivo mouse model for venous thrombosis
The addition of a specific miRNA show reduction in thrombose size in a in-vivo mouse model
- Patent application filed
Les om andre prosjekter:
– A novel biomarker with the potential to improve the lives of millions of UC patients world-wide About the technology Ulcerative Colitis …
– Deep Learning derived Input Function in dynamic PET About the technology With DLIF we present a non-invasive, automatically generated input-function for …
– MicroRNAs for risk assessment and treatment of venous thromboembolism The challenge Venous thromboembolism (VTE) is a highly prevalent disease, affecting around …